Humacyte director granted 80,000 stock options
Humacyte, Inc. director Emery N. Brown received a grant of stock options covering 80,000 shares of common stock at an exercise price of 1.08 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Humacyte, Inc. director Emery N. Brown received a grant of stock options covering 80,000 shares of common stock at an exercise price of 1.08 per share. The options expire on June 11, 2036. One quarter vests on June 11, 2027, with the remainder vesting monthly through June 11, 2030.
Insider Trade Summary
Grant/Award: 80,000 shares
Grant/Award
1 txn
Insider
Brown Emery N.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) | 80,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (right to buy) — 80,000 contracts (Direct)
Holdings Before and After:
Stock Options (right to buy), 0 to 80,000 contracts (Direct)
Footnotes (1)
- F1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.
Key Figures
Options Granted: 80,000 options
Exercise Price: 1.08 per share
Total Options After Grant: 80,000 options
+3 more
6 metrics
Options Granted
80,000 options
Stock options covering common stock granted to director
Exercise Price
1.08 per share
Exercise price for granted stock options
Total Options After Grant
80,000 options
Total derivative securities following transaction
Initial Vesting Date
June 11, 2027
First 25% of options become exercisable
Final Vesting Date
June 11, 2030
Monthly vesting completes on this date
Expiration Date
June 11, 2036
Options expire if not exercised by this date
Key Terms
Stock Options (right to buy), exercise price, expiration date, derivative securities, +1 more
5 terms
Stock Options (right to buy) financial
"security_title: Stock Options (right to buy)"
exercise price financial
"conversion_or_exercise_price: 1.0800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-11T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
derivative securities financial
"derivativeTransactionCount: 1"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
vesting financial
"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Humacyte (HUMA) report for Emery N. Brown?
Humacyte reported that director Emery N. Brown received a grant of stock options for 80,000 shares of common stock. These derivative securities give him the right to buy shares at a fixed exercise price if and when they vest and are exercised.
How many Humacyte (HUMA) stock options were granted to Emery N. Brown?
Emery N. Brown was granted stock options covering 80,000 shares of Humacyte common stock. This entire grant is a derivative award, meaning it represents the right to purchase shares in the future rather than an immediate acquisition of common stock.
What is the exercise price and expiration date of Emery N. Brown’s Humacyte options?
The options granted to Emery N. Brown carry an exercise price of 1.08 per share and expire on June 11, 2036. He may exercise vested options any time before expiration, subject to plan terms and applicable restrictions.
How do Emery N. Brown’s Humacyte (HUMA) stock options vest over time?
The vesting schedule provides that the first 25% of the option becomes exercisable on June 11, 2027. After that date, 1/48 of the option vests monthly on the 11th of each month until June 11, 2030, when vesting completes.
Is Emery N. Brown’s Humacyte option grant an open-market purchase or compensation award?
The filing classifies this transaction as a grant or award acquisition of derivative securities, not an open-market purchase. It represents compensation-related stock options rather than a direct buy of common shares in the market.
How many Humacyte derivative securities does Emery N. Brown hold after this grant?
Following this transaction, Emery N. Brown holds 80,000 stock options according to the filing. These options are derivative securities tied to Humacyte common stock and become exercisable over the specified vesting period through June 11, 2030.
AI-generated analysis. How Rhea-AI works. Not financial advice.
